Healthcare Global Enterprises announced Q1FY24 results: Revenue of Rs 4,607 million in Q1FY24, up 13% YoY. EBITDA of Rs 764 million in Q1FY24, up 5% YoY. Profit After Tax of Rs 110 million in Q1FY24, up 17% YoY. Overall ARPOB stood at Rs 39,686 vs. Rs 38,286 in Q1FY23. Overall AOR stood at 66.9% vs. 61.0% in Q1FY23, a rise of 590 bps. Commenting on the results, Dr. B.S. Ajaikumar, Executive Chairman, HealthCare Global Enterprises said, “HCG’s oncology network, through its presence and depth, uniquely positions the company to address the growing cancer burden in India holistically, while delivering quality cancer care and outcomes. HCG's role today goes beyond mere service provision, extending into pioneering research and academia. We consistently encourage our medical professionals to delve into research, clinical trials, and active participation in global medical conferences and academic pursuits. We are currently working on the low dose immunotherapy & also collaborating with various MNC’s for developing technologies and AI based framework for treatments. HCG strives to be the trusted healthcare partner for every individual battling cancer. We are honored to have earned the trust of our patients and the communities we serve and remain committed to upholding that trust every day." Result PDF